This study on mice was published in the Journal of Neuroimmune Pharmacology in September 2021 and examined the effects of CBD on brain and intestinal inflammation as a result of Multiple Sclerosis as modeled by Experimental Autoimmune Encephalomyelitis (EAE).
The results were very promising at the relatively large oral doses used (20mg/kg), which although not directly comparable, would be the equivalent of a 1400mg dose of CBD for a 150 lb. person.
"These findings demonstrate the beneficial effect of CBD treatment on autoimmune neuroinflammation by ablating expression of pro-inflammatory chemoattractants, regulating inflammatory macrophage activity, promoting MDSC expansion, and limiting the systemic low-grade inflammation in the GI tract, culminating in the attenuation of EAE."
The abstract is here at SpringerLink.